• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Tutrone on phase 3 ARASENS data presented at Northeastern Section of the AUA


“What was found in the sub stratification study was that overall survival favored the addition of darolutamide to ADT and docetaxel in all stratification subgroups,” says Ronald Tutrone, MD, FACS, CPI.

In this video, Ronald Tutrone, MD, FACS, CPI, discusses notable findings from the study, “Overall survival by stratification factors in the phase 3 ARASESNS study of darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel,” presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Tutrone is national medical director of clinical research for United Urology Group, Towson, Maryland.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.